At Tuesday’s closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India’s fifth largest pharma company by market value of ₹57,046 crore. Sun Pharma, Divi’s Lab, Dr. Reddy’s Lab, and Cipla are currently valued between ₹75,284 crore and ₹2.31 lakh crore.
The ₹4,326-crore public issue of Mankind Pharma – the biggest IPO in 2023 so far- was subscribed 15.32 times. It was an offer for sale (OFS) by existing shareholders.
The IPO was the largest ever by a domestic drug maker since Gland Pharma came up with its ₹6,480 crore public issue in November 2020.
“The healthcare sector was a laggard over the last one year but started seeing traction over the last two months as the monthly pharma data showed improvement. Mankind received a good response from its anchor clients given its domestic-focused business with strong brand recall in chronic and consumer healthcare segments,” said Hemang Jani, head of equity strategy at Motilal Oswal Financial Services.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
